bluebird bio, Inc. (0HOH.L)

USD 9.28

(33.91%)

Revenue Summary of bluebird bio, Inc.

  • bluebird bio, Inc.'s latest annual revenue in 2023 was 29.49 Million USD , up 720.04% from previous year.
  • bluebird bio, Inc.'s latest quarterly revenue in 2024 Q2 was 16.1 Million USD , down -13.31% from previous quarter.
  • bluebird bio, Inc. reported a annual revenue of 3.59 Million USD in annual revenue 2022, down -1.77% from previous year.
  • bluebird bio, Inc. reported a annual revenue of 3.66 Million USD in annual revenue 2021, down -98.54% from previous year.
  • bluebird bio, Inc. reported a quarterly revenue of 16.1 Million USD for 2024 Q2, down -13.31% from previous quarter.
  • bluebird bio, Inc. reported a quarterly revenue of 12.39 Million USD for 2023 Q3, up 79.85% from previous quarter.

Annual Revenue Chart of bluebird bio, Inc. (2023 - 2011)

Historical Annual Revenue of bluebird bio, Inc. (2023 - 2011)

Year Revenue Revenue Growth
2023 29.49 Million USD 720.04%
2022 3.59 Million USD -1.77%
2021 3.66 Million USD -98.54%
2020 250.73 Million USD 461.25%
2019 44.67 Million USD -18.15%
2018 54.57 Million USD 54.06%
2017 35.42 Million USD 475.58%
2016 6.15 Million USD -56.28%
2015 14.07 Million USD -44.62%
2014 25.42 Million USD 25.97%
2013 20.18 Million USD 5835.59%
2012 340 Thousand USD -61.45%
2011 882 Thousand USD 0.0%

Peer Revenue Comparison of bluebird bio, Inc.

Name Revenue Revenue Difference
Editas Medicine, Inc. 78.12 Million USD 62.243%
Dynavax Technologies Corporation 232.28 Million USD 87.301%
Supernus Pharmaceuticals, Inc. 607.52 Million USD 95.145%
Perrigo Company plc 4.65 Billion USD 99.366%
Illumina, Inc. 4.5 Billion USD 99.345%
Thermo Fisher Scientific Inc. 42.85 Billion USD 99.931%
Iovance Biotherapeutics, Inc. 1.18 Million USD -2380.824%
Walgreens Boots Alliance, Inc. 147.65 Billion USD 99.98%
IQVIA Holdings Inc. 14.98 Billion USD 99.803%
Heron Therapeutics, Inc. 127.04 Million USD 76.782%
Regeneron Pharmaceuticals, Inc. 13.11 Billion USD 99.775%
Unity Biotechnology, Inc. - USD -Infinity%
Waters Corporation 2.95 Billion USD 99.002%
Biogen Inc. 9.83 Billion USD 99.7%
Sangamo Therapeutics, Inc. 176.23 Million USD 83.262%
Evolus, Inc. 202.08 Million USD 85.404%
Adicet Bio, Inc. - USD -Infinity%
Cara Therapeutics, Inc. 20.96 Million USD -40.676%
Esperion Therapeutics, Inc. 116.33 Million USD 74.645%
FibroGen, Inc. 147.75 Million USD 80.036%
Agilent Technologies, Inc. 6.83 Billion USD 99.568%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
Homology Medicines, Inc. -6.65 Million USD 543.497%
Geron Corporation 237 Thousand USD -12345.992%
Alnylam Pharmaceuticals, Inc. 1.82 Billion USD 98.387%
Amicus Therapeutics, Inc. 399.35 Million USD 92.614%
Myriad Genetics, Inc. 678.4 Million USD 95.652%
Viking Therapeutics, Inc. - USD -Infinity%
Intellia Therapeutics, Inc. 36.27 Million USD 18.685%
Zoetis Inc. 8.54 Billion USD 99.655%
Abeona Therapeutics Inc. 3.5 Million USD -742.771%
Mettler-Toledo International Inc. 3.78 Billion USD 99.221%
BioMarin Pharmaceutical Inc. 2.41 Billion USD 98.781%
Vertex Pharmaceuticals Incorporated 9.86 Billion USD 99.701%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Ionis Pharmaceuticals, Inc. 787.64 Million USD 96.255%
Atara Biotherapeutics, Inc. 8.57 Million USD -244.069%
Verastem, Inc. - USD -Infinity%
Nektar Therapeutics 90.12 Million USD 67.27%
Axsome Therapeutics, Inc. 270.6 Million USD 89.099%
Aclaris Therapeutics, Inc. 31.24 Million USD 5.607%
Sarepta Therapeutics, Inc. 1.24 Billion USD 97.628%
OPKO Health, Inc. 863.49 Million USD 96.584%
Exelixis, Inc. 1.83 Billion USD 98.388%
Neurocrine Biosciences, Inc. 1.88 Billion USD 98.437%
Corcept Therapeutics Incorporated 482.37 Million USD 93.885%
Anavex Life Sciences Corp. - USD -Infinity%
uniQure N.V. 15.84 Million USD -86.183%
Imunon, Inc. - USD -Infinity%
Blueprint Medicines Corporation 249.38 Million USD 88.172%
Insmed Incorporated 305.2 Million USD 90.335%
Halozyme Therapeutics, Inc. 829.25 Million USD 96.443%
Agios Pharmaceuticals, Inc. 26.82 Million USD -9.969%
TG Therapeutics, Inc. 233.66 Million USD 87.376%
Incyte Corporation 3.69 Billion USD 99.202%
Emergent BioSolutions Inc. 1.04 Billion USD 97.189%